Navigation Links
Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters
Date:4/3/2008

Regenerative Medicine leader to expand space and employees in

Massachusetts, encompassing over 250,000 square feet for new global

headquarters

CANTON, Mass., April 3, 2008 /PRNewswire/ -- Joined by local officials and Organogenesis, Inc.'s CEO Geoff MacKay, Governor Deval Patrick announced today that the Massachusetts-based company, which was once planning to move its operations outside of the state, is initiating an expansion of its global headquarters, R&D and manufacturing facilities in Canton.

The Governor's $1 billion Life Sciences Initiative was credited by Organogenesis, the world's leading regenerative medicine company, as a deciding factor in the company's decision to remain and expand in Massachusetts and thereby add hundreds of highly skilled jobs.

"I am pleased that Organogenesis will continue to build its future here in Massachusetts," said Governor Patrick, "This announcement speaks to our commitment to the long-term growth of this industry."

The Massachusetts Office of Business Development worked closely with Organogenesis to create a $12.9 million incentive package. In addition, the state has facilitated $5 million in low-interest loans for growth initiatives. The Life Sciences Initiative bill also addresses tax inequalities when compared with competing states.

"When we first began speaking to the office of Economic Development early last year, Organogenesis had 200 employees, and today, we have 325 with open positions for an additional 50 jobs in 2008 -- all of these being high-skilled positions," said Organogenesis CEO Geoff MacKay. "Driven by both existing high revenue growth and major regulatory approvals, we are well on target for doubling our workforce."

"Governor Patrick, Secretary O'Connell as well as House and Senate leadership, have made a significant commitment to the life sciences sector and we are pleased to see their efforts coming to fruition," continued MacKay. "The Life Sciences Initiative bill solidifies the state of Massachusetts as the best place in the world to translate potentially life saving research into viable, successful businesses."

Currently located at 150 Dan Road, Canton, the new Organogenesis headquarters campus comprises three large buildings encompassing more than 250,000 square feet and within 100 yards of each other:

85 Dan Road

-- Corporate offices will occupy this facility

-- 78,000+ square feet, including 40,000 square feet of currently

built-out office space (the remaining space is empty open bay for

expansion)

-- Upgrades may add up to 10,500 square feet to the building footprint

150 Dan Road

-- To become main research and development labs and pilot manufacturing

site for smaller product lines

-- 79,000+ square feet

275 Dan Road

-- To become main manufacturing facility, including 60,000 square feet of

manufacturing and quality labs, as well as shipping/receiving and

other support systems

-- 95,000+ square feet

Founded in 1985 to commercialize technologies initially discovered at the Massachusetts Institute of Technology (MIT), Canton-based Organogenesis delivers living cell therapy "on demand" to medical clinics. Organogenesis' signature product, Apligraf(R), is the first bio-engineered living cell therapy to have received FDA approvals to close diabetic foot ulcers and venous leg ulcers.

Unveiled last spring, Governor Patrick's life sciences plan includes a 10-year, $1 billion investment package that will both enhance the Commonwealth's already nationally recognized assets in the fields of medicine and science, and fill gaps in federal funding to ensure the state's ability to support life science progress from the idea stage through the production and commercialization stages. Key to the Governor's Life Science Initiative is new legislation that will strengthen the Massachusetts Life Science Center and charge it with the execution of a life science mission focused on science and economic development, strategic investments at critical stages of the development cycle, and collaboration with the private sector to create innovation infrastructure critical to both researchers and companies.

About Regenerative Medicine

A new frontier in healthcare, regenerative medicine utilizes living human cells, including stem cells, to repair or replace body tissue damaged by injury, disease or even the natural aging process.

Regenerative medicine is a multidisciplinary field which brings together biology, medicine, and engineering to empower scientists to grow living cells, tissues and organs in the laboratory, and to safely implant them into the human body for the purposes of healing.

About Organogenesis, Inc.

Massachusetts based Organogenesis, Inc. is the world's most successful regenerative medicine company and is focused in areas of bio-active wound healing, bio-surgery and bio-aesthetics. Organogenesis delivers living tissue "on demand," and its mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care.

Organogenesis is in the midst of a large expansion, both in the U.S., as well as overseas. As the world's leading Regenerative Medicine company, Organogenesis has broadened its international scope and ties over the past few years. The company has recently established European headquarters located in Switzerland. In addition, last December the company announced an agreement with China's National Tissue Engineering Center (NTEC), a leading stem cell and regenerative medicine consortium, headquartered in Shanghai, for the commercialization of Organogenesis, Inc. technology within the Chinese market, and potentially throughout Asia. For more information, visit http://www.organogenesis.com.


'/>"/>
SOURCE Organogenesis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
2. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
3. MUSCs Kilpatrick to Address Congress Regarding PTSD Care
4. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Dendreon Announces $47 Million Registered Direct Offering
8. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
9. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
10. MiMedx Group Announces Post-split Name Change
11. Millennium Announces $200,000 Purchase Order From Greek Distributor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led by ... in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The article ... coronary artery disease (CAD). Lam is an assistant professor at the Department of ...
(Date:3/27/2017)... 27, 2017 DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is now ... for U.S. consumers who want to have their DarioHealth ... signed strategic alliance agreements with partners across the U.S. ... and if approved, will supply and bill the customer,s ...
(Date:3/24/2017)... , March 24, 2017 MiMedx Group, ... company utilizing human placental tissue allografts and patent-protected processes ... multiple sectors of healthcare, announced today  that it will ... New York , NY.  Parker H. "Pete" Petit, ... Financial Officer, Christopher M. Cashman , EVP and ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research ... Stem Cell (hESC) Research - Global Strategic Business Report" report ... ... Cell (hESC) Research in US$ Million. Annual estimates and forecasts are ... are derived from primary and secondary research. The ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
Breaking Biology News(10 mins):